Keating, Armand

Professor & Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation

BSc (Ottawa), MD (Ottawa)

Main Appointments

  • Division of Hematology, Department of Medicine
  • Director, Cell Therapy Program & Philip S. Orsino Facility for Cell Therapy, Princess Margaret Hospital / Ontario Cancer Institute
  • Senior Scientist, Division of Experimental Therapeutics, Toronto General Research Institute, University Health Network

Additional Appointments

  • Institute of Biomaterials & Biomedical Engineering

Contact Information

Princess Margaret Hospital
610 University Avenue, Suite 5-303
Toronto, Ontario M5G 2M9 Canada

+1 416 946-4595 (office)
armand.keating@uhn.on.ca (email)
Cell Therapy Program (web)


Research Themes

Research Interests

The Princess Margaret Hospital Cell Therapy Program under Dr Keating incorporates the Orsino Cell Therapy Translational Research Laboratory located at the  Princess Margaret Hospital (PMH) , the Orsino Facility for Cell Therapy (located at PMH) and the REMEDI Cell Manipulation Facility (located at the Toronto General Hospital). The Program is highly integrated and intensely collaborative and  focuses on two aspects of cell therapy

One focus involves cell-based anti-cancer therapy which spans the gamut of research from signal transduction pathways of cytolytic activity in NK cells to the use of different cell types (NK cells, NK cell lines, gamma delta T cells, antigen-specific cytotoxic T cells) in the treatment of a variety of cancers, including the lymphomas, chronic myeloid leukemia, acute leukemia and multiple myeloma. While translational research is a key component of the Program, there is a strong commitment to initiate early phase clinical trials to treat these malignancies. A state-of-the-art Good Manufacturing Practice (cGMP) facility (the Orsino Facility) at PMH enables complex cell therapy protocols to be undertaken and a multidisciplinary team is in place to conduct the cell therapy clinical trials.

The other research focus is on regenerative medicine, especially on the role of mesenchymal stromal cells (MSCs) and hematopoietic progenitor cells in repairing a variety of tissues including heart, lung, kidney, spinal cord, blood vessels and in wound healing. These studies are done in collaboration with leading investigators in the respective fields. The work spans mechanistic in vitro and pre-clinical animal (generally murine) studies and extends to the development and initiation of early phase clinical trials.

The PMH Cell Therapy Program is located on the 5th floor in Suite 5-303, PMH, 610 University Avenue, Toronto and staff include the Associate Director (Sowmya Viswanathan PhD), projects officer (Karen Chang MSc), senior technologist (TBA), clinical trials co-ordinator (Jan McCrae RN), clinical research fellow (Pierre Villeneuve MD PhD) and a research fellow and visiting professor (Joaquin Martinez MD).  The  Orsino Cell Therapy Translational Research Laboratory is located at PMH 4th Floor 4-605,. The laboratory staff currently includes the lab manager (Dr Xing-Hua Wang), 5 postdoctoral fellows (Victor Dayan MD, Paula Filomeno MD [supervised by Dr Peter Ferguson], Yoko Kosaka PhD, Gabrielle Siegers PhD, Gustavo Yannarelli PhD) and 5 graduate students (Jen Bikow [for MSc], Sonia Montanari [for PhD], Iran Rashedi [for PhD], Brenna Swift [for MSc], Brent Williams MD FRCPC [for PhD]).

Select Publications

Keating A, How do Mesenchymal Stromal Cells Suppress T Cells?  Cell Stem Cell. 2:106-108,2008.

Rose RA, Jiang H, Wang XH, Helke S, Tsoporis J, Gong N, Keating S, Parker TG, Backx PH, Keating A. Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype and do not become functional cardiomyocytes. Stem Cells 26: 2884-92,2008.

Wong A, Keating A, Lu W, Duchesneau P, Wang X, Sacher A, Hu J, Stripp B, Waddell T.  Identification of a bone marrow-derived epithelial-like population capable of  repopulating injured mouse airway epithelium. J. Clin. Invest. 119:336-348,2009.

Seshadri T and Keating A, Is there a Role for Autotransplants in AML in First Remission? Biol. Blood Marrow Transplant. 15:(suppl 1) 17-20, 2008.

Gupta, V.; Tomblyn, M.; Pedersen, T.L Atkins, H.L.; Battiwalla, M.; Gress, R.E.; Pollack, M.S.; Storek, J.; Thompson, J.C.; Tiberghien, P.; Young, J-A.H.; Ribaud, P.; Horowitz, M. Keating, A. Allogeneic hematopoietic cell transplantation in HIV-positive patients with hematological disorders: A report from the Center for International Blood and Marrow  Transplant  Research (CIBMTR). Biol. Blood Marrow Transplant. 15: 864-71, 2009

Sarugaser R, Hanoun L, Keating A, Stanford W L, and Davies JE.  Mesenchymal stem cells self-renew and differentiate according to a deterministic hierarchy. PloS ONE 4: e6498, 2009.

Perform an automatic PubMed search of this researcher’s publications